These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 38939389)
1. Rivaroxaban vs Vitamin K Antagonist in Patients With Atrial Fibrillation and Advanced Chronic Kidney Disease. Kreutz R; Deray G; Floege J; Gwechenberger M; Hahn K; Luft AR; Persson P; Axthelm C; Beer JH; Bergler-Klein J; Lellouche N; Taggeselle J; Coleman CI; Beyer-Westendorf J; JACC Adv; 2024 Feb; 3(2):100813. PubMed ID: 38939389 [TBL] [Abstract][Full Text] [Related]
2. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses. Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628 [TBL] [Abstract][Full Text] [Related]
3. Cardiovascular and renal outcomes in patients with atrial fibrillation and stage 4-5 chronic kidney disease receiving direct oral anticoagulants: a multicenter retrospective cohort study. Lin Y; Chao TF; Tsai ML; Tseng CJ; Wang TH; Chang CH; Lin YS; Yang NI; Chu PH; Hung MJ; Wu VC; Chen TH J Thromb Thrombolysis; 2024 Jan; 57(1):89-100. PubMed ID: 37605063 [TBL] [Abstract][Full Text] [Related]
4. Cardiorenal Outcomes Among Patients With Atrial Fibrillation Treated With Oral Anticoagulants. Trevisan M; Hjemdahl P; Clase CM; de Jong Y; Evans M; Bellocco R; Fu EL; Carrero JJ Am J Kidney Dis; 2023 Mar; 81(3):307-317.e1. PubMed ID: 36208798 [TBL] [Abstract][Full Text] [Related]
5. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions. Cheng JW; Barillari G J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983 [TBL] [Abstract][Full Text] [Related]
6. Risk Profiles and Treatment Patterns in Atrial Fibrillation Patients with Chronic Kidney Disease Receiving or not Receiving Anticoagulation Therapy. Kreutz R; Deray G; Floege J; Gwechenberger M; Hahn K; Luft AR; Persson P; Axthelm C; Beer JH; Bergler-Klein J; Lellouche N; Taggeselle J; Beyer-Westendorf J TH Open; 2024 Jan; 8(1):e106-e113. PubMed ID: 38406259 [No Abstract] [Full Text] [Related]
7. Safety and Efficacy of Vitamin K Antagonists versus Rivaroxaban in Hemodialysis Patients with Atrial Fibrillation: A Multicenter Randomized Controlled Trial. De Vriese AS; Caluwé R; Van Der Meersch H; De Boeck K; De Bacquer D J Am Soc Nephrol; 2021 Jun; 32(6):1474-1483. PubMed ID: 33753537 [TBL] [Abstract][Full Text] [Related]
8. Safety and Effectiveness of Rivaroxaban Versus Warfarin Across GFR Levels in Atrial Fibrillation: A Population-Based Study in Australia and Canada. Ha JT; Scaria A; Andrade J; Badve SV; Birks P; Bota SE; Campain A; Djurdjev O; Garg AX; Harel Z; Hemmelgarn B; Hockham C; James MT; Jardine MJ; Lam D; Levin A; McArthur E; Ravani P; Shao S; Sood MM; Tan Z; Tangri N; Whitlock R; Gallagher M; Jun M Kidney Med; 2023 Jul; 5(7):100675. PubMed ID: 37492112 [TBL] [Abstract][Full Text] [Related]
9. Risk of Cardiovascular Events and Mortality Among Elderly Patients With Reduced GFR Receiving Direct Oral Anticoagulants. Ashley J; McArthur E; Bota S; Harel Z; Battistella M; Molnar AO; Jun M; Badve SV; Garg AX; Manuel D; Tanuseputro P; Wells P; Mavrakanas T; Rhodes E; Sood MM Am J Kidney Dis; 2020 Sep; 76(3):311-320. PubMed ID: 32333946 [TBL] [Abstract][Full Text] [Related]
11. Number needed to treat based on real-world evidence for non-vitamin K antagonist oral anticoagulants versus vitamin K antagonist oral anticoagulants in stroke prevention in patients with non-valvular atrial fibrillation. Briere JB; Bowrin K; Millier A; Toumi M; Wojciechowski P; Taieb V J Med Econ; 2019 Aug; 22(8):760-765. PubMed ID: 30969801 [No Abstract] [Full Text] [Related]
12. Clinical outcomes with rivaroxaban in patients transitioned from vitamin K antagonist therapy: a subgroup analysis of a randomized trial. Mahaffey KW; Wojdyla D; Hankey GJ; White HD; Nessel CC; Piccini JP; Patel MR; Berkowitz SD; Becker RC; Halperin JL; Singer DE; Califf RM; Fox KA; Breithardt G; Hacke W Ann Intern Med; 2013 Jun; 158(12):861-8. PubMed ID: 23778903 [TBL] [Abstract][Full Text] [Related]
13. The INVICTUS rheumatic heart disease research program: Rationale, design and baseline characteristics of a randomized trial of rivaroxaban compared to vitamin K antagonists in rheumatic valvular disease and atrial fibrillation. Karthikeyan G; Connolly SJ; Ntsekhe M; Benz A; Rangarajan S; Lewis G; Yun Y; Sharma SK; Maklady F; Elghamrawy AE; Kazmi K; Cabral TTJ; Dayi H; Changsheng M; Gitura BM; Avezum A; Zuhlke L; Lwabi P; Haileamlak A; Ogah O; Chillo P; Paniagua M; ElSayed A; Dans A; Gondwe-Chunda L; Molefe-Baikai OJ; Gonzalez-Hermosillo JA; Hakim J; Damasceno A; Kamanzi ER; Musuku J; Davletov K; Connolly K; Mayosi BM; Yusuf S; Am Heart J; 2020 Jul; 225():69-77. PubMed ID: 32474206 [TBL] [Abstract][Full Text] [Related]
14. Bleeding risk with rivaroxaban compared with vitamin K antagonists in patients aged 80 years or older with atrial fibrillation. Hanon O; Vidal JS; Pisica-Donose G; Orvoën G; David JP; Chaussade E; Caillard L; de Jong LW; Boulloche N; Vinsonneau U; Bouée S; Krolak-Salmon P; Fauchier L; Jouanny P; Sacco G; Bellarbre F; Belmin J; Puisieux F; Lilamand M; Paillaud E; Boureau AS; Heart; 2021 Sep; 107(17):1376-1382. PubMed ID: 33262185 [TBL] [Abstract][Full Text] [Related]
15. Renal outcomes of rivaroxaban compared with warfarin in Asian patients with nonvalvular atrial fibrillation: A nationwide population-based cohort study. Lee SR; Choi EK; Park SH; Han KD; Oh S; Abdelgawwad K; Lip GYH Front Cardiovasc Med; 2023; 10():1040834. PubMed ID: 36910528 [TBL] [Abstract][Full Text] [Related]
16. Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation. Bruins Slot KM; Berge E Cochrane Database Syst Rev; 2013 Aug; (8):CD008980. PubMed ID: 23925867 [TBL] [Abstract][Full Text] [Related]
17. Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II). Steinberg BA; Shrader P; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Hylek E; Kowey PR; Mahaffey KW; O'Brien EC; Singer DE; Peterson ED; Piccini JP; Am Heart J; 2017 Jul; 189():40-47. PubMed ID: 28625380 [TBL] [Abstract][Full Text] [Related]
18. Renal Outcomes in Anticoagulated Patients With Atrial Fibrillation. Yao X; Tangri N; Gersh BJ; Sangaralingham LR; Shah ND; Nath KA; Noseworthy PA J Am Coll Cardiol; 2017 Nov; 70(21):2621-2632. PubMed ID: 29169468 [TBL] [Abstract][Full Text] [Related]
19. Comparisons of Rivaroxaban Following Different Dosage Criteria (ROCKET AF or J-ROCKET AF Trials) in Asian Patients With Atrial Fibrillation. Chan YH; Lee HF; Wang CL; Chang SH; Yeh CH; Chao TF; Yeh YH; Chen SA; Kuo CT J Am Heart Assoc; 2019 Nov; 8(21):e013053. PubMed ID: 31623498 [TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and a history of cancer: observations from ROCKET AF. Chen ST; Hellkamp AS; Becker RC; Berkowitz SD; Breithardt G; Fox KAA; Hacke W; Halperin JL; Hankey GJ; Mahaffey KW; Nessel CC; Piccini JP; Singer DE; Patel MR; Melloni C Eur Heart J Qual Care Clin Outcomes; 2019 Apr; 5(2):145-152. PubMed ID: 30219887 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]